SGYP - Synergy Pharmaceuticals Stock Price, News & Analysis

$1.90 -0.02 (-1.04 %)
(As of 11/24/2017 09:57 AM ET)
Previous Close$1.92
Today's Range$1.89 - $1.94
52-Week Range$1.68 - $7.15
Volume6.09 million shs
Average Volume5.96 million shs
Market Capitalization$468.65 million
P/E RatioN/A
Dividend YieldN/A
Beta1061.37

About Synergy Pharmaceuticals (NASDAQ:SGYP)

Synergy Pharmaceuticals logoSynergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders. TRULANCE is designed to replicate the function of uroguanylin. Dolcanatide is being evaluated for inflammatory bowel disease (IBD). TRULANCE is approved in the United States under the trademark name TRULANCE, for the treatment of adults with chronic idiopathic constipation (CIC). In addition, it is developing TRULANCE for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Dolcanatide is designed to be an analog of uroguanylin with enhanced resistance to standard digestive breakdown by proteases in the intestine.


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SGYP
CUSIP87163930

Debt

Debt-to-Equity Ratio-68.13%
Current Ratio4.26%
Quick Ratio3.88%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.01) per share
Price / Book-190.00

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($1.16)
Net Income$-198,600,000.00
Net MarginsN/A
Return on Equity-540.19%
Return on Assets-195.92%

Miscellaneous

Employees116
Outstanding Shares246,660,000

Frequently Asked Questions for Synergy Pharmaceuticals (NASDAQ:SGYP)

What is Synergy Pharmaceuticals' stock symbol?

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

How were Synergy Pharmaceuticals' earnings last quarter?

Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) released its quarterly earnings data on Thursday, November, 9th. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.06. The biopharmaceutical company had revenue of $5.01 million for the quarter, compared to the consensus estimate of $4.53 million. During the same period in the previous year, the business posted ($0.22) earnings per share. View Synergy Pharmaceuticals' Earnings History.

Where is Synergy Pharmaceuticals' stock going? Where will Synergy Pharmaceuticals' stock price be in 2017?

10 analysts have issued 1-year price targets for Synergy Pharmaceuticals' stock. Their predictions range from $2.50 to $15.00. On average, they expect Synergy Pharmaceuticals' share price to reach $8.40 in the next year. View Analyst Ratings for Synergy Pharmaceuticals.

What are Wall Street analysts saying about Synergy Pharmaceuticals stock?

Here are some recent quotes from research analysts about Synergy Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York. " (11/9/2017)
  • 2. HC Wainwright analysts commented, "We note that the launch of Trulance appears to be progressing on multiple fronts, with the company having reached 66% of its targeted prescriber base and over 90% of the high-volume prescribers (deciles 8-10). According to QuintilesIMS data, as of mid-2017 over 12,600 Trulance prescriptions had been filled and total monthly prescription volume has increased on average over 182% month-over-month during that period. Over 32% of all high prescribers had written a Trulance prescription since the drug was launched earlier this year, with an average increase for all prescribers of approximately 140% month-over-month. Trulance achieved 6.8% new-to-brand prescription (NBRx) total market share and 12% NBRx market share among gastroenterologists. Importantly, about 55% of new Trulance prescriptions filled since launch were coming from new patients not previously on a branded prescription treatment and 45% were patients who converted from other branded prescription treatments." (8/10/2017)
  • 3. Cantor Fitzgerald analysts commented, "Management upbeat about early returns. SGYP reported 2Q17 results and posted a new corporate presentation to provide an update of the Trulance launch (here). We spoke with management (no results call was held) to hear its views regarding how the launch is proceeding. Acknowledging the inherent positive bias of company managements that have launched their inaugural product, we believe metrics provided by SGYP may, however, show an objective snapshot of the launch." (8/10/2017)

Are investors shorting Synergy Pharmaceuticals?

Synergy Pharmaceuticals saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 68,882,733 shares, an increase of 3.1% from the October 13th total of 66,832,410 shares. Based on an average daily volume of 5,384,794 shares, the short-interest ratio is presently 12.8 days. Approximately 30.7% of the company's stock are short sold.

Who are some of Synergy Pharmaceuticals' key competitors?

Who are Synergy Pharmaceuticals' key executives?

Synergy Pharmaceuticals' management team includes the folowing people:

  • Gary S. Jacob Ph.D., Chairman of the Board, President, Chief Executive Officer (Age 70)
  • Gary G. Gemignani, Chief Financial Officer, Executive Vice President (Age 52)
  • Marino Garcia, Executive Vice President, Chief Strategy Officer (Age 50)
  • Patrick H. Griffin M.D., Executive Vice President, Chief Medical Officer (Age 61)
  • Troy Hamilton, Executive Vice President, Chief Commercial Officer (Age 45)
  • Melvin K. Spigelman M.D., Lead Independent Director (Age 68)
  • Thomas H. Adams Jr. Ph.D., Independent Director (Age 74)
  • John P. Brancaccio CPA, Independent Director (Age 69)
  • Timothy S. Callahan, Independent Director (Age 46)
  • Richard J. Daly, Independent Director (Age 64)

Who owns Synergy Pharmaceuticals stock?

Synergy Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Orbimed Advisors LLC (6.06%), JPMorgan Chase & Co. (1.51%), Pictet Asset Management Ltd. (1.16%), Alyeska Investment Group L.P. (1.05%), OxFORD Asset Management LLP (0.91%) and Cheyne Capital Management UK LLP (0.72%). Company insiders that own Synergy Pharmaceuticals stock include Gary S Jacob, John P Brancaccio and Paulson & Co Inc. View Institutional Ownership Trends for Synergy Pharmaceuticals.

Who sold Synergy Pharmaceuticals stock? Who is selling Synergy Pharmaceuticals stock?

Synergy Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Axiom International Investors LLC DE, Asymmetry Capital Management L.P., California State Teachers Retirement System, Schwab Charles Investment Management Inc. and Cambridge Investment Research Advisors Inc.. View Insider Buying and Selling for Synergy Pharmaceuticals.

Who bought Synergy Pharmaceuticals stock? Who is buying Synergy Pharmaceuticals stock?

Synergy Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Cheyne Capital Management UK LLP, JPMorgan Chase & Co., Hikari Power Ltd, Alyeska Investment Group L.P., Pictet Asset Management Ltd., OxFORD Asset Management LLP, Brown Advisory Inc. and Cornerstone Capital Management Holdings LLC.. Company insiders that have bought Synergy Pharmaceuticals stock in the last two years include Gary S Jacob and John P Brancaccio. View Insider Buying and Selling for Synergy Pharmaceuticals.

How do I buy Synergy Pharmaceuticals stock?

Shares of Synergy Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Synergy Pharmaceuticals' stock price today?

One share of Synergy Pharmaceuticals stock can currently be purchased for approximately $1.90.

How big of a company is Synergy Pharmaceuticals?

Synergy Pharmaceuticals has a market capitalization of $468.65 million. The biopharmaceutical company earns $-198,600,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Synergy Pharmaceuticals employs 116 workers across the globe.

How can I contact Synergy Pharmaceuticals?

Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]


MarketBeat Community Rating for Synergy Pharmaceuticals (SGYP)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  466 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  635
MarketBeat's community ratings are surveys of what our community members think about Synergy Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Synergy Pharmaceuticals (NASDAQ:SGYP)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 0 Hold Ratings, 9 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $8.40 (342.11% upside)

Consensus Price Target History for Synergy Pharmaceuticals (NASDAQ:SGYP)

Price Target History for Synergy Pharmaceuticals (NASDAQ:SGYP)

Analysts' Ratings History for Synergy Pharmaceuticals (NASDAQ:SGYP)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/21/2017Cantor FitzgeraldReiterated RatingBuy$10.00N/AView Rating Details
11/14/2017BTIG ResearchReiterated RatingBuy$7.00N/AView Rating Details
11/12/2017Canaccord GenuitySet Price TargetBuy$13.00N/AView Rating Details
10/18/2017HC WainwrightSet Price TargetBuy$8.00N/AView Rating Details
10/10/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$6.00N/AView Rating Details
9/13/2017Citigroup Inc.Reiterated RatingSell -> Sell$3.20 -> $2.50MediumView Rating Details
9/8/2017CIBCLower Price TargetOutperform -> Outperform$9.00 -> $6.00LowView Rating Details
8/10/2017Rodman & RenshawLower Price TargetBuy -> Buy$18.00 -> $15.00HighView Rating Details
3/2/2017GuggenheimReiterated RatingOutperform$10.00N/AView Rating Details
12/15/2016Roth CapitalReiterated RatingBuy$6.50N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Synergy Pharmaceuticals (NASDAQ:SGYP)

Earnings by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Earnings History by Quarter for Synergy Pharmaceuticals (NASDAQ SGYP)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.28)($0.22)$4.53 million$5.01 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.25)($0.33)$1.98 million$2.31 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.23)($0.30)$0.10 million$0.10 millionViewN/AView Earnings Details
3/1/2017Q4 2016($0.20)($0.31)ViewN/AView Earnings Details
8/8/2016Q216($0.20)($0.23)ViewN/AView Earnings Details
5/10/2016Q1($0.23)($0.51)ViewN/AView Earnings Details
11/9/2015Q315($0.28)($0.23)ViewN/AView Earnings Details
8/10/2015Q215($0.28)($0.34)$102.00 millionViewN/AView Earnings Details
5/11/2015Q115($0.33)($0.28)ViewN/AView Earnings Details
3/16/2015($0.28)($0.32)ViewN/AView Earnings Details
11/10/2014($0.28)($0.24)ViewN/AView Earnings Details
8/11/2014($0.23)($0.28)ViewN/AView Earnings Details
5/13/2014Q114($0.23)($0.18)ViewN/AView Earnings Details
3/17/2014Q4 13($0.20)($0.22)ViewN/AView Earnings Details
11/12/2013Q3($0.17)($0.15)ViewN/AView Earnings Details
11/13/2012Q312($0.01)($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Synergy Pharmaceuticals (NASDAQ:SGYP)
2017 EPS Consensus Estimate: ($0.83)
2018 EPS Consensus Estimate: ($0.64)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.16)($0.16)($0.16)
Q2 20171($0.22)($0.22)($0.22)
Q3 20171($0.25)($0.25)($0.25)
Q4 20171($0.20)($0.20)($0.20)
Q1 20181($0.16)($0.16)($0.16)
Q2 20181($0.17)($0.17)($0.17)
Q3 20181($0.16)($0.16)($0.16)
Q4 20181($0.15)($0.15)($0.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Synergy Pharmaceuticals (NASDAQ:SGYP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Synergy Pharmaceuticals (NASDAQ SGYP)

Insider Ownership Percentage: 3.80%
Institutional Ownership Percentage: 66.03%
Insider Trades by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)
Institutional Ownership by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Insider Trades by Quarter for Synergy Pharmaceuticals (NASDAQ SGYP)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/10/2017Paulson & Co. Inc.Major ShareholderSell8,750,000$2.82$24,675,000.00View SEC Filing  
8/7/2017Paulson & Co. Inc.Major ShareholderSell26,287$3.77$99,101.99View SEC Filing  
5/26/2017Gary S JacobCEOBuy5,680$3.52$19,993.60View SEC Filing  
5/26/2017John P BrancaccioDirectorBuy6,500$3.59$23,335.00View SEC Filing  
11/4/2016Paulson & Co. Inc.Major ShareholderSell140,000$4.24$593,600.00View SEC Filing  
9/28/2016Paulson & Co. Inc.Major ShareholderSell54,300$5.69$308,967.00View SEC Filing  
9/19/2016John P BrancaccioDirectorSell2,518$5.76$14,503.68View SEC Filing  
9/19/2016Paulson & Co. Inc.Major ShareholderSell3,473,713$5.61$19,487,529.93View SEC Filing  
9/14/2015Bernard DenoyerSVPSell10,000$7.50$75,000.00View SEC Filing  
9/11/2015Alan JoslynDirectorSell13,754$7.22$99,303.88View SEC Filing  
6/3/2014John P BrancaccioDirectorBuy3,500$4.12$14,420.00View SEC Filing  
5/27/2014Gary S JacobCEOBuy4,000$4.18$16,720.00View SEC Filing  
5/23/2014Bernard DenoyerSVPBuy2,500$3.89$9,725.00View SEC Filing  
5/23/2014Kunwar ShailubhaiInsiderBuy3,000$3.89$11,670.00View SEC Filing  
10/29/2013Gabriel CerroneDirectorBuy12,000$4.09$49,080.00View SEC Filing  
6/21/2013Bernard DenoyerSVPBuy7,500$4.78$35,850.00View SEC Filing  
6/14/2013Gabriel CerroneChairmanBuy8,000$4.42$35,360.00View SEC Filing  
4/24/2013Gabriel CerroneChairmanBuy5,500$4.66$25,630.00View SEC Filing  
2/5/2013Gabriel CerroneChairmanBuy5,000$6.15$30,750.00View SEC Filing  
2/4/2013Gabriel CerroneChairmanBuy13,090$6.04$79,063.60View SEC Filing  
1/30/2013Gabriel CerroneChairmanBuy26,000$5.98$155,480.00View SEC Filing  
11/14/2012Gabriel CerroneChairmanBuy87,820$3.61$317,030.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Synergy Pharmaceuticals (NASDAQ SGYP)

Source:
DateHeadline
Synergy Pharmaceuticals: What Will It Take To Rebound? - Seeking AlphaSynergy Pharmaceuticals: What Will It Take To Rebound? - Seeking Alpha
seekingalpha.com - November 23 at 10:25 AM
Synergy Pharmaceuticals, Inc. (SGYP) Receives Buy Rating from Cantor FitzgeraldSynergy Pharmaceuticals, Inc. (SGYP) Receives Buy Rating from Cantor Fitzgerald
www.americanbankingnews.com - November 22 at 1:42 PM
First Week Of SGYP July 2018 Options TradingFirst Week Of SGYP July 2018 Options Trading
www.thestreet.com - November 22 at 7:53 AM
Inside Synergy Pharmaceuticals: Your Investor OverviewInside Synergy Pharmaceuticals: Your Investor Overview
finance.yahoo.com - November 22 at 7:53 AM
An Overview of Trulance: Synergy Pharmaceuticals’ First Commercialized DrugAn Overview of Trulance: Synergy Pharmaceuticals’ First Commercialized Drug
finance.yahoo.com - November 22 at 7:53 AM
Behind Synergy Pharmaceuticals’ Financials TodayBehind Synergy Pharmaceuticals’ Financials Today
finance.yahoo.com - November 22 at 7:53 AM
Synergy Pharmaceuticals Is Facing These Risks This NovemberSynergy Pharmaceuticals Is Facing These Risks This November
finance.yahoo.com - November 22 at 7:53 AM
This $12 Billion Hedge Fund Is Switching to Synergy Pharmaceuticals, Away from ACADIAThis $12 Billion Hedge Fund Is Switching to Synergy Pharmaceuticals, Away from ACADIA
finance.yahoo.com - November 21 at 10:22 AM
Synergy Pharmaceuticals: Balancing Trust With Value - Seeking AlphaSynergy Pharmaceuticals: Balancing Trust With Value - Seeking Alpha
seekingalpha.com - November 18 at 11:55 AM
Synergy Pharmaceuticals, Inc. (SGYP) Receives Buy Rating from BTIG ResearchSynergy Pharmaceuticals, Inc. (SGYP) Receives Buy Rating from BTIG Research
www.americanbankingnews.com - November 15 at 2:06 PM
General Electric, Synergy Pharma Stuck Again in Tuesday’s 52-Week Low ClubGeneral Electric, Synergy Pharma Stuck Again in Tuesday’s 52-Week Low Club
247wallst.com - November 15 at 8:26 AM
Pre-Market Technical Recap on Drug Makers Stocks -- Synergy Pharma, Novo Nordisk, United Therapeutics, and DepomedPre-Market Technical Recap on Drug Makers Stocks -- Synergy Pharma, Novo Nordisk, United Therapeutics, and Depomed
www.bizjournals.com - November 15 at 8:26 AM
Insider Selling: Synergy Pharmaceuticals, Inc. (SGYP) Major Shareholder Sells 8,750,000 Shares of StockInsider Selling: Synergy Pharmaceuticals, Inc. (SGYP) Major Shareholder Sells 8,750,000 Shares of Stock
www.americanbankingnews.com - November 14 at 7:40 PM
Synergy Pharmaceuticals, Inc. (SGYP) Expected to Post Quarterly Sales of $11.72 MillionSynergy Pharmaceuticals, Inc. (SGYP) Expected to Post Quarterly Sales of $11.72 Million
www.americanbankingnews.com - November 14 at 10:15 AM
Synergy Pharma (SGYP) Prices Common Stock and Warrant OfferingSynergy Pharma (SGYP) Prices Common Stock and Warrant Offering
www.streetinsider.com - November 14 at 7:51 AM
Synergy Pharmaceuticals Announces Pricing of Offering of Common Stock and WarrantsSynergy Pharmaceuticals Announces Pricing of Offering of Common Stock and Warrants
finance.yahoo.com - November 14 at 7:51 AM
BTIG Suggests One Stock to Buy and One to Proceed with CautionBTIG Suggests One Stock to Buy and One to Proceed with Caution
finance.yahoo.com - November 14 at 7:51 AM
Synergy Pharmaceuticals (SGYP) PT Lowered to $7 at BTIG; Factoring Risk of Additional Equity Financings by Late ... - StreetInsider.comSynergy Pharmaceuticals (SGYP) PT Lowered to $7 at BTIG; 'Factoring Risk of Additional Equity Financings by Late ... - StreetInsider.com
www.streetinsider.com - November 14 at 7:51 AM
Synergy Pharmaceuticals, Inc. (SGYP) Given a $13.00 Price Target at Canaccord GenuitySynergy Pharmaceuticals, Inc. (SGYP) Given a $13.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - November 13 at 4:00 PM
Synergy Pharmaceuticals prices equity offering; shares down 7%Synergy Pharmaceuticals prices equity offering; shares down 7%
seekingalpha.com - November 13 at 10:25 AM
Synergy Pharmaceuticals, Inc. (SGYP) Given Consensus Recommendation of "Hold" by AnalystsSynergy Pharmaceuticals, Inc. (SGYP) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 12 at 8:13 PM
 Analysts Expect Synergy Pharmaceuticals, Inc. (SGYP) to Post -$0.22 EPS Analysts Expect Synergy Pharmaceuticals, Inc. (SGYP) to Post -$0.22 EPS
www.americanbankingnews.com - November 12 at 1:50 PM
After Hours Most Active for Nov 10, 2017 : F, SGYP, GE, RICE, BAC, AAPL, LC, CLF, MU, MDLZ, CELG, QQQ - NasdaqAfter Hours Most Active for Nov 10, 2017 : F, SGYP, GE, RICE, BAC, AAPL, LC, CLF, MU, MDLZ, CELG, QQQ - Nasdaq
www.nasdaq.com - November 11 at 1:32 PM
Synergy Pharmaceuticals: Momentum Ahead Of IBS-C Approval For Trulance - Seeking AlphaSynergy Pharmaceuticals: Momentum Ahead Of IBS-C Approval For Trulance - Seeking Alpha
seekingalpha.com - November 11 at 1:32 PM
Synergy Pharmaceuticals, Inc. (SGYP) Short Interest Up 3.1% in OctoberSynergy Pharmaceuticals, Inc. (SGYP) Short Interest Up 3.1% in October
www.americanbankingnews.com - November 11 at 1:50 AM
Synergy Pharmaceuticals (SGYP) CEO Gary Jacob on Q3 2017 ... - Seeking AlphaSynergy Pharmaceuticals' (SGYP) CEO Gary Jacob on Q3 2017 ... - Seeking Alpha
seekingalpha.com - November 10 at 12:05 PM
Synergy Pharmaceuticals Q3: Delivering The Goods - Seeking AlphaSynergy Pharmaceuticals Q3: Delivering The Goods - Seeking Alpha
seekingalpha.com - November 10 at 12:05 PM
Edited Transcript of SGYP earnings conference call or presentation 9-Nov-17 9:30pm GMTEdited Transcript of SGYP earnings conference call or presentation 9-Nov-17 9:30pm GMT
finance.yahoo.com - November 10 at 12:05 PM
Synergy Pharmaceuticals, Inc. (SGYP) Posts Quarterly  Earnings Results, Beats Expectations By $0.06 EPSSynergy Pharmaceuticals, Inc. (SGYP) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - November 9 at 11:22 PM
Synergy Pharmaceuticals Reports Third Quarter 2017 Financial Results and Business UpdateSynergy Pharmaceuticals Reports Third Quarter 2017 Financial Results and Business Update
finance.yahoo.com - November 9 at 6:21 PM
Synergy Pharmaceuticals Reports Third Quarter 2017 Financial Results and Business Update - Business Wire (press release)Synergy Pharmaceuticals Reports Third Quarter 2017 Financial Results and Business Update - Business Wire (press release)
www.businesswire.com - November 9 at 6:20 PM
Synergy Pharmaceuticals, Inc. to Host Earnings CallSynergy Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 1:19 PM
Synergy Pharmaceuticals, Inc. (SGYP) Stock Rating Upgraded by Zacks Investment ResearchSynergy Pharmaceuticals, Inc. (SGYP) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 9 at 7:04 AM
Synergys Potential Is Undervalued - Seeking AlphaSynergy's Potential Is Undervalued - Seeking Alpha
seekingalpha.com - November 4 at 2:52 PM
Synergy Pharmaceuticals to Report Third Quarter 2017 Financial Results and Host Conference Call and WebcastSynergy Pharmaceuticals to Report Third Quarter 2017 Financial Results and Host Conference Call and Webcast
finance.yahoo.com - November 1 at 8:43 AM
First Week Of SGYP December 15th Options TradingFirst Week Of SGYP December 15th Options Trading
www.thestreet.com - October 27 at 5:59 PM
Synergy Pharmaceuticals Inc (SGYP): A 2018 Story Shapes UpSynergy Pharmaceuticals Inc (SGYP): A 2018 Story Shapes Up
finance.yahoo.com - October 27 at 5:59 PM
Synergy Pharmaceuticals, Inc. (SGYP) Sees Large Growth in Short InterestSynergy Pharmaceuticals, Inc. (SGYP) Sees Large Growth in Short Interest
www.americanbankingnews.com - October 26 at 1:40 AM
Zacks: Analysts Anticipate Synergy Pharmaceuticals, Inc. (SGYP) Will Announce Quarterly Sales of $5.76 MillionZacks: Analysts Anticipate Synergy Pharmaceuticals, Inc. (SGYP) Will Announce Quarterly Sales of $5.76 Million
www.americanbankingnews.com - October 25 at 6:44 PM
Synergy Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SGYP-US : October 19, 2017Synergy Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SGYP-US : October 19, 2017
finance.yahoo.com - October 19 at 8:45 AM
Synergy Pharmaceuticals, Inc. (SGYP) Given Average Recommendation of "Hold" by AnalystsSynergy Pharmaceuticals, Inc. (SGYP) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - October 18 at 11:02 PM
Synergy Pharmaceuticals (SGYP) versus The Competition Financial ComparisonSynergy Pharmaceuticals (SGYP) versus The Competition Financial Comparison
www.americanbankingnews.com - October 18 at 4:26 PM
Synergy Pharma (SGYP) Presents Results from Study Examining ... - StreetInsider.comSynergy Pharma (SGYP) Presents Results from Study Examining ... - StreetInsider.com
www.streetinsider.com - October 18 at 8:27 AM
Synergy Pharma (SGYP) Presents Results from Study Examining Patient and Physician Perceptions and Experiences with IBS-CSynergy Pharma (SGYP) Presents Results from Study Examining Patient and Physician Perceptions and Experiences with IBS-C
www.streetinsider.com - October 18 at 8:27 AM
Synergy Pharmaceuticals Presents Results from Study Examining Patient and Physician Perceptions and Experiences with Irritable Bowel Syndrome with Constipation (IBS-C)Synergy Pharmaceuticals Presents Results from Study Examining Patient and Physician Perceptions and Experiences with Irritable Bowel Syndrome with Constipation (IBS-C)
finance.yahoo.com - October 18 at 8:27 AM
Technical Snapshots for These Drug Makers Stocks -- SciClone Pharma, Synergy Pharma, Novo Nordisk, and United ... - PR Newswire (press release)Technical Snapshots for These Drug Makers Stocks -- SciClone Pharma, Synergy Pharma, Novo Nordisk, and United ... - PR Newswire (press release)
www.prnewswire.com - October 17 at 7:13 AM
Synergy Pharmaceuticals, Inc. (SGYP) Given a $8.00 Price Target at HC WainwrightSynergy Pharmaceuticals, Inc. (SGYP) Given a $8.00 Price Target at HC Wainwright
www.americanbankingnews.com - October 15 at 10:56 PM
Reviewing Synergy Pharmaceuticals (SGYP) and Its PeersReviewing Synergy Pharmaceuticals (SGYP) and Its Peers
www.americanbankingnews.com - October 13 at 2:24 AM
Synergy Pharmaceuticals, Inc. (SGYP) Sees Significant Drop in Short InterestSynergy Pharmaceuticals, Inc. (SGYP) Sees Significant Drop in Short Interest
www.americanbankingnews.com - October 13 at 1:58 AM
Synergy Pharma (SGYP) to Highlight New Data for TRULANCE at WCOG - StreetInsider.comSynergy Pharma (SGYP) to Highlight New Data for TRULANCE at WCOG - StreetInsider.com
www.streetinsider.com - October 12 at 4:04 PM

Social Media

Financials

Chart

Synergy Pharmaceuticals (NASDAQ SGYP) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.